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ABSTRACT Poliovirus exists as three stable serotypes
(PV-1, PV-2, and PV-3). These viruses display three antigenic
sites each, designated N-AgI, N-AgII, and N-AgIU. When mice
are immunized with poliovirus, N-AgI is the major neutraliza-
tion antigenic site for PV-3, whereas N-Agl and N-AgHI are
immunodominant over N-AgI for PV-1. To study the relation-
ship between structure and antigenicity, a hybrid virus was
constructed in which N-AgI of PV-1 was replaced by N-AgI of
PV-3. PV-3- and PV-1-specific antisera, including those elicited
by PV-3 in primates, neutralized the hybrid virus. Injection of
the hybrid virus into rabbits or into primates resulted in the
production of antisera that neutralized both PV-1 and PV-3.
The data show that sequence replacement at N-AgI of polio-
virus is compatible with viral proliferation, an observation
useful for the development of multivalent picornavirus vac-
cines.
Poliovirus causes poliomyelitis, an acute disease of the
central nervous system that leads to paralysis or death.
Although two excellent poliovirus vaccines (inactivated virus
and live attenuated virus; see refs. 1 and 2 and references
therein) are used in developed countries, poliomyelitis re-
mains a serious health problem worldwide. The total eradi-
cation of circulating poliovirus is desirable and, indeed, is a
goal of international health organizations. However, this
requires continuing research on the physical and biological
properties ofthe poliovirion, its pathway of infection, and the
response of the immune system to virus infection. We report
here the construction of a hybrid poliovirus that carries
neutralization epitopes of two different serotypes of
poliovirus. 11
Poliovirus is a picornavirus whose naked capsid is com-
posed of 60 copies each of viral polypeptides VP1 and VP3,
68 or 69 copies ofVP2 and VP4, and 1 or 2 copies of VPO, the
precursor to VP2 and VP4 (3). The polypeptide shell encloses
a single-stranded positive-sense RNA genome about 7500
nucleotides long (4). The genome sequences of representa-
tives of all three serotypes of poliovirus (including the Sabin
vaccine strains) have been determined and found to be
closely related (4-9).
Each of the three poliovirus serotypes is defined by its
ability to elicit neutralizing antibodies that are not capable of
neutralizing the other two serotypes. Work in several labo-
ratories has led to the discovery of three independent
neutralizing antigenic sites (N-Ags) and their neutralization
epitopes of poliovirus (see refs. 10-16 for further references).
The solution of the three-dimensional structure of the polio-
virion has subsequently permitted the mapping of the N-Ags
to specific surface regions of the viral particle (17). Interest-
ingly, the antigenic structure of poliovirus was found to be
nearly identical to that of human rhinovirus 14 (18).
Of the three N-Ags, N-AgI is a continuous sequence of
amino acids mapping to positions 90-105 from the N terminus
of capsid protein VP1 (Fig. 1C). Amino acids 96-104 of VP1
are located at the apex of the viral particle and exist as a loop
that is particularly well exposed (17). N-AgI of PV-1 is
recognized by two exceptional neutralizing monoclonal an-
tibodies (N-mAbs C2 and 95) even after denaturation of
capsid protein VP1 (20, 21). The other two neutralization
antigenic sites (N-AgII and N-AgIII) are discontinuous in
nature. N-AgII is composed of amino acids in the region
220-222 from the N terminus of VP1 plus amino acids
164-175 ofVP2. N-AgIII is composed ofamino acids 286-290
from the N terminus ofVP1 plus amino acids 58-60 and 71-79
from the N terminus of VP3.
A paradox appeared during the early studies of the anti-
genicity of poliovirus. PV-1 elicited N-mAbs in Balb/c mice
that recognized N-AgII and N-AgIII but not N-AgI. On the
other hand, the N-mAbs isolated from Balb/c mice inocu-
lated with PV-3 exclusively recognized N-AgI (see the
discussion by Wimmer et al. in ref. 22). This paradox was
solved in that the phenomenon of different immunodomin-
ance of N-Ags of poliovirus types was found predominantly
when specific strains of inbred mice were used for the
monoclonal antibody production. In outbred mammals the
immunodominance of a particular N-Ag over others is much
less apparent (23). Considering the close relationship of the
poliovirus serotypes in regard to primary structure, the
different responses of immune systems to the different
serotypes remain an unexplained observation.
The unique structure of N-AgI within the poliovirion and
its peculiar interaction with the immune system makes it an
ideal target for in vitro induced mutagenesis. It is of interest
to investigate what amino acids in this loop determine type
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clature suggested by Rueckert and Wimmer (31) is used for virus-
specific polypeptides in which capsid proteins VP4, VP2, VP3, and
VP1 also are called 1A, 1B, 1C, and 1D, respectively.
tTo whom reprint requests should be addressed.
tPresent address: Department of Biology 156-29, California Institute
of Technology, Pasadena, CA 91125.
I1An account of this work has been presented in part (by M.G.M.,
R.J.K., and E.W.) at the Seventh International Congress of
Virology, Aug. 9-14, 1987, Edmonton, AB, Canada, p. 137 (abstr.).
3203
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
3204 Medical Sciences: Murray et al.
polio 7525
P01,10I
* polio cDNA
polio _ _ C] pBR322
_
T7 qene 10 promoter
90 100
PV-3 V A E V D N E Q P T T R A B
GTG CC AT TAT T GAGG TCG ACAACG AG C AAC CCAC C ACC CIGGG CGC AA'A
kTACGCACCGGTAAT AACTC.CAGCTGTTGCTCGTTGGGTGGT GGG1CC CGCGTTTTCGA
I~~~~~ ~S HtA,Soh ~~~~~Sail Sinal H~indilL
z..XflxA'iie ~r ._ N-AgI
C
FIG. 1. Schematic representation of the strategy to construct a
poliovirus type 1/type 3 hybrid virus. (A) Plasmid pT7PV-1/3, a
derivative of transcription vector pT7PV1-5 (28), was constructed as
described in the text. It contains the phage 17 (qbT7) promoter for T7
RNA polymerase and the cDNA sequence of PV-1(M) in which a
small DNA segment encoding the amino acid sequence N-AgI was
replaced with that of PV-3(L). (B) Sequence corresponding to a
region specifying N-AgI of PV-3(L). (C) The loop is located near the
apex of the poliovirion (17); C was redrawn from a figure published
by Hogle et al. (17).
specificity and to what extent amino acids in this loop can be
modified without losing viability of the virus. Such study can
be the basis of the development of multivalent picornavirus
vaccines.
MATERIALS AND METHODS
Oligonucleotide-Mediated Site-Specific Mutagenesis of
PV-1. The construction of the mutagenesis cartridge was
achieved by cloning the appropriate PV-1 fragments into
phage M13mplO (24) followed by site-directed mutagenesis of
the poliovirus genome (25). Single-strand template DNA was
prepared in Escherichia coli strain BW313, (dut- ung-) (26),
and its sequence was altered by mismatch oligonucleotides as
described (25). Details of the protocol will be published
elsewhere. Mutants were identified by restriction enzyme
analysis and nucleotide sequencing.
Immunizations and Neutralization Assays. The hybrid virus
was grown on monolayer HeLa cells and harvested after
complete CPE (-48 hr). Approximately 10 ,ug oftotal protein
(determined by the Lowry method or by colorimetry with the
brilliant blue G-250 Bio-Rad kit) in a volume of 50 IlI was
emulsified 1:1 with incomplete Freund's adjuvant and in-
jected into female New Zealand White rabbits via a peri-
popliteal lymph node route. At the same time, -50 ,ug (total
protein) was emulsified 1:1 with complete Freund's adjuvant
and injected via the subcutaneous (25 ,ug) and intramuscular
(25 ,ug) routes. At 10- to 14-day intervals, three boosters with
50 ,ug of CsCl-purified virus emulsified 1:1 with incomplete
Freund's adjuvant were injected intramuscularly into the
rabbits' gastronemeous muscle. Cynomolgus monkeys were
twice injected subcutaneously with doses of hybrid virus as
indicated in Table 4. Sera were withdrawn at regular intervals
and tested for their ability to neutralize different strains of
poliovirus.
Two different assays were used to assess the neutralizing
titers of immune sera. First, plaque reduction assays were
performed essentially as described by Emini et al. (19).
Briefly, virus stocks were diluted by serial 1:10 dilution; 0.1
ml of each dilution was incubated with 0.1 ml of undiluted
antiserum for 1 hr at room temperature. Each mixture was
then used to infect confluent HeLa cell monolayers growing
in six-well dishes (Falcon 3046). Plaques were then counted
at -48 hr postinfection after staining with crystal violet or
neutral red. Second, serial dilutions of sera were titered by
their ability to neutralize a fixed dose of poliovirus (100
TCID50; TCID50 is the dose required to infect 50% ofthe cells
in tissue culture).
RESULTS
We have asked the question whether the replacement of
N-AgI in PV-1 strain Mahoney [PV-1(M)] with N-AgI ofPV-3
strain Leon [PV-3(L)] is compatible with viral proliferation
and, if so, whether the exchanged sequence will be an active
determinant participating in the induction of neutralizing
antibodies and in neutralization. To facilitate virtually un-
limited genetic variation of N-AgI, we constructed a muta-
genesis cartridge (Fig. 1B) in this region. We followed a
strategy previously used by us to produce mutants in the
genome-linked protein VPg of poliovirus (27). A synthetic
double-stranded DNA segment encoding N-AgI ofPV-3 (Fig.
1B) was inserted between a naturally occurring Sph I restric-
tion site (nucleotide number 2732 of PV-1) and a newly
generated HindIIl site (nucleotide number 2786) replacing the
existing PV-1 sequences. All nucleotide changes necessary
for cloning and insertion of the mutagenesis cartridge pre-
served the expected amino acid sequence of the virus. After
genetic manipulation, the poliovirus-specific cDNA fragment
was engineered into a vector containing the phage T7 pro-
moter (Fig. L4) shown previously by us to yield highly
infectious poliovirus RNA after transcription by T7 RNA
polymerase (28). Viral RNA was prepared in vitro and used
to transfect HeLa cells. Wild-type virus or mutants contain-
ing amino acid replacements in region 88-102 of VP1 were
isolated 36 hr after transfection and plaque-purified for
further analyses. All constructs generated prior to transfec-
tions were analyzed by primer extension sequencing tech-
niques (29). Similarly, genomic RNA of mutant virus was
sequenced to confirm the presence of the nucleotide replace-
ments.
Transfection of HeLa cells with run-off transcripts of
pT7PV-1/3 yielded virus whose genomic RNA had the
expected PV-1/PV-3 hybrid sequence (unpublished data).
We will call this virus W1/3-1D-1, following a nomenclature
suggested by Bernstein et al. (30); 1D denotes capsid poly-
peptide VP1 (31). At 37°C this hybrid virus had a small plaque
phenotype, and virus yield in standard one-step growth
experiments was <10o relative to wild-type PV-1(M) virus
(Fig. 2).
The amino acid differences in N-AgI between strains of
poliovirus and neutralization escape mutants are shown in
Table 1. It is apparent that this region exhibits high inter-
serotypic amino acid diversity. Nine amino acid differences
exist between N-AgI ofPV-1(M) and PV-3(L), many ofwhich
are changes in charge or size. Similarly, mutations leading to
neutralization resistance involved a wide variety of different
amino acid exchanges. Therefore, this region is unlikely to
play an essential role in the folding pathway of the capsid
precursors (aggregation of capsid precursor P1 and its pro-
teolytic processing products VPO, VP3, and VP1) or in
encapsidation, or else the numerous mutations leading to
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FIG. 2. One-step growth curve comparing replication of the
hybrid virus with that of PV-1(M). Confluent HeLa cell monolayers
growing in 60-mm tissue culture plates (Falcon 3001) were infected
at a multiplicity of infection of 20 in a volume of 0.3 ml. Virus was
adsorbed for 30 min at room temperature; then prewarmed medium
was added, and cells were placed at 37°C in 95% air/5% CO2. At the
indicated time points, medium was aspirated, and the cells were
washed twice with phosphate-buffered saline and then scraped from
the plate into a 1.5-ml tube. Any remaining cells were collected by
washing the plate with 1.0 ml of phosphate-buffered saline and
combining this wash with the cells. Cells were pelleted and resus-
pended in 100 Al of buffer (0.1 M NaCI/0.1 M Tris/0.0015 M MgCI2,
pH 7.35) and lysed by freezing and thawing three times. Nuclei were
pelleted by centrifugation, and the virus containing supernatant was
collected and titered by plaque assay as described.
neutralization resistance would not be tolerable. This is
underscored by our observation that the hybrid virus is viable
Table 2. Serological characterization of the hybrid virus with
polyclonal serotype-specific hyperimmune sera
Virus titer, log1o pfu'mlV
Serum PV-1 PV-3 PV-1/PV-3 hybrid
Monkey preimmune 8.9 8.7 8.8
Monkey anti-PV-3 9.0 <2.0 3.4
Rabbit anti-PV-1 <0.3 7.8 <0.3
Horse anti-PV-3 9.0 <0.3 <0.3
Virus titers were determined by the standard plaque-reduction
assays (19).
although it is impaired in growth efficiency. The viability of
the hybrid virus obtained from in vitro recombinant DNA is
in contrast to acDNA construct in which a much larger region
of VP1 of PV-3 (Sabin) was engineered into PV-1 (Sabin).
This cDNA construct did not yield virus upon transfection of
HeLa cells (32). Replacement of the entire capsid region of
type 1 poliovirus with that of type 3 poliovirus, on the other
hand, has been reported to yield viable virus (33).
The antigenic properties of the type 1/type 3 hybrid virus
were analyzed by using polyclonal and monoclonal antisera.
The serotype-specific hyperimmune sera effectively neutral-
ized the homologous serotype virus, resulting in a reduction
of the titer by >8 log1o (Table 2). The intertypic hybrid virus
was neutralized by anti-PV-1(M) serum to the same extent as
PV-1(M), an observation suggesting that the replacement of
N-AgI in W1/3-1D-1 did not influence the accessibility or
activity of N-AgII and N-AgIII. The hybrid virus was also
neutralized significantly with monkey anti-PV-3(L), although
the reduction of the plaque titer amounted to only -5 log1o.
As expected, the hybrid virus was not neutralized by N-mAb
95, an antibody that specifically recognizes N-AgI in PV-1(M)
(21), but it was neutralized by N-mAbs 175, 194, and 204,
Table 1. Amino acid sequences of the region spanning N-AgI of various poliovirus types and strains
90 95 100 105
PV-1(M)* CVTIMTVDNPASTTNKDKLFAVW
PV-1(Sabin) -- A-I----S---K------T--
Neutralization escape mutants of PV-1 1- - - - - - - - - - - - - - D--------
2--------------K--------
PV-2(L) --A-IE---D-P-KRAS---S--
PV-2(Sabin) --A-IE---D-P-KRASR--S--
Neutralization escape mutants of PV-2 1 - - - - - - - - - - - - - - P - - - - - - - -
2---------------D-------
3-------------E---------
4-------------N---------
PV-3(L) -- A-IE---EQP--RAQ----M-
PV-3(Sabin) -- A-IE---EQP--RAQ----M-
Neutralization escape mutants of PV-3 1- - - - - - - N - - - - - - - - - - - - - - -
2-----G-----------------
3-----K-----------------
4------------I----------
5------------A----------
6------------N----------
7 ------------- N ---------
8 ------------- I .---------
9.----------.---Q.------
10--------------w--------
11---------------T-------
12---------------V-------
13----------------L------
14.---_____________P_____
15----------------R------
16----------------H------
*Amino acid sequence is given in the single-letter code and is numbered according to the sequence of
VP1 of PV-1(M). The numbering may be slightly different in VP1 polypeptides of other serotypes
because of deletions or insertions. Data are compiled from refs. 10-16.
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Table 3. Serological characterization of the hybrid virus with
neutralizing N-mAb
Titer of N-mAb specific for N-AgI*
Virus 95t 175* 1940 204*
PV-1(M) 32 <2 <1 <1
PV-3(L) <4 1024 1024 >8192
PV-1/PV-3 hybrid
W1/3-lD-1 <4 8192 256 >8192
*Inverse of the dilution of antibody sufficient to neutralize 100
TCID50.
tAnti-PV-1(M) N-mAb 95 as described in ref. 21.
tAnti-PV-3(L) N-mAbs as described in ref. 11.
three antibodies specific for N-AgI ofPV-3(L) (11, 14) (Table
3). Moreover, two N-mAbs specific for N-AgII (N-mAb H9)
and N-AgIII (N-mAb D3) ofPV-1(M) (13, 15) neutralized the
hybrid virus (data not shown).
The observation that hybrid virus W1/3-1D-1 expresses
type 1 and type 3-specific neutralization determinants
prompted us to investigate whether it could also elicit type 1-
and type 3-specific antibodies upon injection into rabbits. The
sera obtained from four (offour) rabbits neutralized PV-1(M),
PV-3(L), and the hybrid virus but had no significant effect on
the infectivity of PV-2 strain Lansing [PV-2(L)] (Fig. 3).
W1/3-1D-1 virus was also injected subcutaneously into
cynomolgus monkeys, and each animal's immune response
was measured. Immunization with 104 plaque-forming units
(pfu) of hybrid virus followed by a boost of 107 pfu 4 weeks
later showed significant titers of neutralizing antibodies
against PV-1(M) and PV-1/PV-3 hybrid virus, but only a
weak titer against PV-3(L) virus (Table 4). No neutralizing
activity was observed against PV-2 strain MEF1 [PV-
2(MEF1)] poliovirus. However, when the experiment was
carried out in similar manner but with 107 pfu in the primary
injection, significant neutralizing titers were observed against
PV-1(M), PV-3(L), and the PV-1/PV-3 hybrid virus.
DISCUSSION
We have shown that a hybrid virus carrying neutralization
antigenic sites oftwo different serotypes of poliovirus can be
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Table 4. Immunization of monkeys with hybrid virus
Serum titer of samples 1-6, 1/dilution
neutralizing TCID50
Virus 1 2 3 4 5 6
Experiment 1 (monkey 2269)*
PV-1(M) <4 <4 16 64 64 1024
PV-3(L) <4 <4 <4 <4 <4 16
PV-1/3 hybrid <4 <4 16 64 64 4096
PV-2(MEF1) <4 <4 <4 <4 <4 <4
Experiment 2 (monkey 2270)t
PV-1(M) <4 16 1024 1024 1024 1024
PV-3(L) <4 16 64 64 64 256
PV-1/3 hybrid <4 64 1024 1024 1024 1024
PV-2(MEF1) <4 <4 <4 <4 <4 <4
*The animal was inoculated subcutaneously with 104 pfu of PV-
1/PV-3 hybrid virus (W1/3-1D-1) and given a booster after 4 weeks
with 107 pfu of hybrid virus by the same route. Serum samples were
withdrawn upon the first injection (sample 1) and then in weekly
intervals (samples 2-5). Ten days after the booster injection, the
final sample (6) was withdrawn.
tImmunization schedule as in experiment 1 except that the first
inoculation was with 107 pfu of hybrid virus.
neutralized by corresponding type-specific neutralizing anti-
bodies and can elicit the corresponding type-specific anti-
bodies. These observations demonstrate two important
points (see also ref. 34). First, in the context of the PV-1(M)
sequences, the PV-3(L) insert assumes a conformation that
allows binding of and neutralization with type 3-specific
antibodies. Thus, the hybrid virus allows an assay for the
type 3-specific neutralization epitopes of N-AgI indepen-
dently of other antigenic sites of the poliovirion. Second, the
type 3-specific loop in PV-3(L) and also in the PV-1/PV-3
hybrid virus is recognized by the primate immune system.
The fact that the neutralization antigenic site of one
poliovirus can be replaced by a sequence with numerous
amino acid changes suggests that the loop comprising this
antigenic region can be replaced by heterogenous sequences
representing antigenic determinants of other human patho-
gens. Of immediate interest to us are sequences from corre-
PV-3 (Leon)
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FIG. 3. Elicitation of type 1- and
type 3-specific neutralizing antibodies
by the PV-1/PV-3 hybrid virus (W1/3-
iD-1). Standard plaque reduction as-
says were performed as described for
Table 2. Antibody PI is rabbit preim-
mune serum. Antibody PV-1/PV-3 is
serum from rabbits made hyperim-
mune to the hybrid virus, and anti-
bodies PV-1, PV-2, and PV-3 are sera
from rabbits made hyperimmune to
PV-1(M), PV-2(L), and PV-3(L),
respectively.
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sponding regions of human rhinovirus 14(18) and of hepatitis
A virus, two other picornaviruses. The construction of a
hybrid virus containing a dominant N-Ag of hepatitis A virus
could lead to the development of a highly effective, oral
anti-hepatitis A virus vaccine. No such vaccine against
infectious hepatitis is currently commercially available. Be-
cause of the enormous serological diversity of the human
rhinoviruses, a hybrid PV-1-human rhinovirus 14 virus
appears to be only of academic interest.
A small but significant incidence of poliomyelitis occurs
every year in the United States in spite of extensive vacci-
dation and the virtual elimination of wild-type strains from
circulation (35). Most of these cases have been classified as
vaccine-associated, and it is highly likely that genetic variants
of the type 2 and type 3 Sabin strains, but to a much lesser
extent variants of Sabin type 1 vaccine virus, are the cause
of disease in vaccine recipients or their contacts (for an
extensive discussion, see refs. 2 and 35). Because of the
antigenic properties of the type 1/type 3 hybrid virus re-
ported here, we propose that genetically engineered hybrid
viruses similar to W1/3-1D-1 but constructed from cDNA
clones of the Sabin strain derivatives may be useful in the
primary vaccination of children to reduce vaccine-associated
cases of poliomyelitis.
Note Added in Proof. A type 1/3 hybrid virus similar to but not
identical with that described here was obtained also by Burke et al.
(36). Moreover, a hybrid virus consisting of type 1 (Mahoney) whose
N-AgI Was replaced with N-AgI of poliovirus type 2 (Lansing) has
been constructed recently by A. Martin, C. Wychowski, M. Girard,
T. Couderc, M. Tardy-Panit, and R. Crainic** and by M.G.M., J.
Bradley, X.-F. Yang, E.W., E. G. Moss, and V. R. Racaniello
(unpublished 4ata). The type 1/2 hybrid virus was found to be
neurovirulent in mice.
**This was reported at the ICN-UCI International Conference of
Virology, "Molecular Aspects of Picornavirus Infection and
Detection," Jan. 14 and 15, 1988, Newport Beach, CA.
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